A Word About May
1 August 2013 In Allies & Partnerships
We just wanted to take a minute and give some long-overdue thanks to the fabulous corporate allies who helped us run a successful Melanoma Awareness Month back in May! Through online and in-store efforts, the allies helped raise funds for MRA’s scientific research programs and also increased awareness of...
Melanoma Research Alliance Rings Closing Bell at the New York Stock Exchange
26 June 2013 In Events
[youtube url=http://www.youtube.com/watch?v=_Emq_T2GO5Y] We had a fabulous visibility opportunity yesterday: The Melanoma Research Alliance (MRA) rang the closing bell on the NYSE trading floor on Tuesday, June 25. Surrounded by MRA leadership and supporters, MRA Co-Founder and Chair Debra Black presided over the ceremony, which signaled the end of the day’s trading.
Changing Perceptions and Building a Business on Safe Sun: Guest Post by Mott 50
Mott 50 Co-Founders Anne Botica Reilly and Monique Moore[/caption] This summer Mott 50 is introducing the Pale is Pretty campaign— a social awareness initiative designed to encourage people to think critically about their sun safety practices and pledge to ‘Practice Safe Sun.’ Our mission at Mott 50 is to...
A Teenager’s View: Keeping Sun Fun and Avoiding Melanoma
By Langley Grace Wallace Over the past 40 years, melanoma has increased 800% in young women and 400% in young men. Recently, melanoma has become the most common cancer among 25-29 year olds, and even teenagers are developing this deadly skin cancer.
Two MRA-Sponsored Investigators Published Papers in the New England Journal of Medicine
12 June 2013 In News
Two MRA-sponsored investigators recently reported on the clinical testing of immune checkpoint inhibitors targeting a pathway known as PD-1 in the New England Journal of Medicine. This therapeutic approach, whose clinical utility was established by the FDA approval of ipilimumab in 2011, has produced promising data in patients with advanced melanoma.
New Melanoma Therapies Approved
31 May 2013 In News
These are the best types of posts to write: On Wednesday, the US Food and Drug Administration (FDA) approved two genetically-targeted melanoma therapies as well as a companion diagnostic test that will be used to determine which patients' tumors carry the specific genetic mutations the treatments target.
Safe Sun Style: Guest Post from Meg of SPF Love
30 May 2013 In Allies & Partnerships
It's a common misconception that sun safety is not fashion-forward. Our guest blogger and May ally SPF Love begs to differ. [caption id="attachment_203" align="aligncenter" width="300"] Meg of SPF Love[/caption] I'm honored to be guest blogging for MRA. I started my journey over a year ago when I decided to start...
MRA & Leveraged Finance Fights Melanoma Video Series
19 May 2013 In Events
[brightcove vid=2372187009001&exp3=1405557362001&surl=http://c.brightcove.com/services&pubid=1405556719001&pk=AQ~~,AAABR0G1fZk~,HNsXz5NC104V7oLZ6aVapLmHmSUC2yKF&w=480&h=270] MRA is holding its 2nd annual Leveraged Finance Fights Melanoma event next week in NYC. Our friends at Privcap produced a series of videos featuring people from the leveraged finance community who have been touched by melanoma.
Adjuvant Therapy Advocacy ASCO Awareness Board Members BRAF Cancer Combination Therapy Detection FDA Grants Immunotherapy Melanoma microbiome MRA Partners Patient Forum Patient Stories Patient-Centric Care Patients Pediatric Melanoma Prevention Research Science Social Media Targeted Therapy Teens Treatment Wendy Selig Young Investigators Young People